Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A

B. Svenstrup*, J. Herrstedt, N. Brünner, P. Bennett, H. Wachmann, P. Dombernowsky

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstrakt

    30 postmenopausal patients with metastatic breast cancer were treated with three different doses of fadrozole hydrochloride (CGS 169 49A), a non-steroidal competitive aromatase inhibitor. The effect of 0.5, 1 and 2 mg given twice daily upon the levels of oestrogens, their androgen precursors and upon the concentration of sex hormone binding globulin (SHBG) was investigated after 1 and 3 months and then every 3 months until progression of disease. A significant reduction in the serum concentration of oestrone (P < 0.0001) was obtained at all doses. Also, the serum concentration of oestrone sulphate was significantly reduced (P < 0.001). However, after 1 month, the concentration was significantly different from pretreatment levels (P < 0.01) only at the 4 mg daily dose. A decline was also observed in the concentration of SHBG (P < 0.05), with a concomitant elevation of the percentage non-SHBG-bound oestradiol. The androgens, testosterone and dehydroepiandrosterone sulphate, were unaltered during treatment, while androstendione was significantly elevated at the 2 mg daily dose (P < 0.001).

    OriginalsprogEngelsk
    Sider (fra-til)1254-1258
    Antal sider5
    TidsskriftEuropean Journal of Cancer
    Vol/bind30
    Udgave nummer9
    DOI
    StatusUdgivet - 1994

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A' indeholder.

    Citationsformater